Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1893-1903

  Du, Ning ^a   Feng, Jiang ^b   Hu, Li Juan ^a   Sun, Xin ^a   Sun, Hai Bing ^a   Zhao, Yang ^a   Yang, Yi Ping ^c   Ren, Hong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b YAN'AN UNIVERSITY   (China)

^c Shaanxi Provincial Tumor Hospital   (China)

Author keywords

Angiotensin II type 1 receptor; Breast cancer cell; CREB; Cyclin D1; ERK; NF B; p53; PCNA; Proliferation; Ras

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAF PROTEIN; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR POTENTIAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; APOPTOSIS; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CREB-BINDING PROTEIN; CYCLIN D1; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROLIFERATING CELL NUCLEAR ANTIGEN; RAF KINASES; RAS PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860752363     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1720     Document Type: Article

References (37)

1. Courneya KS, Mackey JR and McKenzie DC: Exercise for breast cancer survivors: research evidence and clinical guidelines. Phys Sports Med 30: 33-42, 2002. (Pubitemid 34855991)
2. Lever AF, Hole DJ, Gillis CR, et al: Do inhibitors of angiotensin- I-converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998. (Pubitemid 28327802)
3. Gallinat S, Busche S, Raizada MK and Sumners C: The angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol Endocrinol Metab 278: E357-E374, 2000. (Pubitemid 30149379)
4. Ino K, Shibata K, Kajiyama H, Nawa A, Nomura S and Kikkawa F: Manipulating the angiotensin system: new approaches to the treatment of solid tumors. Expert Opin Biol Ther 6: 243-255, 2006. (Pubitemid 43344744)
5. Kikkawa F, Mizuno M, Shibata K, et al: Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 190: 1258-1263, 2004. (Pubitemid 38692206)
6. Suganuma T, Ino K, Shibata K, et al: Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11: 2686-2694, 2005. (Pubitemid 40569470)
7. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al: Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90: 1059-1068, 2004. (Pubitemid 38495829)
8. Egami K, Murohara T, Shimada T, et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75, 2003. (Pubitemid 38056377)
9. Molteni A, Ward WF, Ts'ao CH, et al: Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type 1 receptor antagonists. Curr Pharm Des 9: 751-761, PMID: 2003.
10. Fujita M, Hayashi I, Yamashina S, Itoman M and Majima M: Blockade of angiotensin AT1R a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294: 441-447, 2002. (Pubitemid 34694114)
11. Noguchi R, Yoshiji H, Kuriyama S, et al: Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9: 6038-6045, 2003. (Pubitemid 38018091)
12. Yasumaru M, Tsuji S, Tsujii M, et al: Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63: 6726-6734, 2003. (Pubitemid 37322952)
13. Ohashi H, Takagi H, Oh H, et al: Phosphatidylinositol 3- kinase/ Akt regulates angiotensin .-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 94: 785-793, 2004. (Pubitemid 38451740)
14. Watanabe Y, Shibata K, Kikkawa F, et al: Adipocyte derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via rennin-angiotensin system. Clin Cancer Res 9: 6497-6503, 2003. (Pubitemid 38031839)
15. Ino K, Uehara C, Kikkawa F, et al: Enhancement of aminopeptidase A expression during angiotensin II-induced choriocarcinoma cell proliferation through AT1R receptor involving protein kinase C and mitogen-activated protein kinase-dependent signaling pathway. J Clin Endocrinol Metab 88: 3973-3982, 2003. (Pubitemid 37034554)
16. Lam KY and Leung PS: Regulation and expression of a reninangiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol 146: 567-572, 2002. (Pubitemid 34436471)
17. Kucerová D, Zelezná B, Sloncová E and Sovová V: Angiotensin II receptors on colorectal carcinoma cells. Int J Mol Med 2: 593-595, 1998.
18. Greco S, Muscella A, Elia MG, et al: Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196: 370-377, 2003. (Pubitemid 36775885)
19. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334: 661-665, 1988.
20. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT Raf/MEK ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218, 2004. (Pubitemid 38240034)
21. Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B and Sotelo J: Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92: 1247-1252, 2005. (Pubitemid 40604399)
22. Ager EI, Neo J and Christophi C: The renin-angiotensin system and malignancy. Carcinogenesis 29: 1675-1684, 2008.
23. Deshayes F and Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16: 293-299, 2005. (Pubitemid 41206635)
24. Uemura H, Ishiguro H, Nakaigawa N, et al: Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2: 1139-1147, 2003.
25. Takeda H and Kondo S: Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158: 1633-1637, 2001. (Pubitemid 32422928)
26. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y and Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12: 2888-2893, 2006.
27. Fujimoto Y, Sasaki T, Tsuchida A and Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495: 197-200, 2001. (Pubitemid 32397704)
28. Huang W, Yu LF, Zhong J, et al: Angiotensin II type 1 receptor expression in human gastric cancer and induces MMP2 and MMP9 expression in MKN-28 cells. Dig Dis Sci 53: 163-168, 2008. (Pubitemid 350265665)
29. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T and Hayakawa M: Angiotensin . type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179, 2002. (Pubitemid 34830392)
30. Zhao Y, Chen X, Cai L, Yang Y, Sui G and Wu J: Angiotensin II suppresses adriamycin-induced apoptosis through activation of phosphatidylinositol 3-kinase/Akt signaling in human breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 40: 304-310, 2008. (Pubitemid 351572111)
31. + ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 173: 315-323, 2002.
32. Saito Y and Berk BC: Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 33: 3-7, 2001. (Pubitemid 32127779)
33. Weber AJ, Soong G, Bryan R, Saba S and Prince A: Activation of NF-κB in airway epithelial cells is dependent on CFTR trafficking and Cl-channel function. Am J Physiol Lung Cell Mol Physiol 281: L71-L78, 2001.
34. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
35. Aaltomaa S, Lipponen P and Syrjanen K: Prognostic value of cell proliferation in breast cancer as determined by proliferating cell nuclear antigen (PCNA) immunostaining. Anticancer Res 12: 1281-1286, 1992.
36. Zafonte BT, Hulit J, Amanatullah DF, et al: Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell-cycle. Front Biosci 5: 938-961, 2000.
37. Kenny FS, Hui R, Musgrove EA, et al: Over-expression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5: 2069-2076, 1999. (Pubitemid 29399260)